On November 15, 2024, Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanded approval of its cancer drug Keytruda. The recommendation is for Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adults with unresectable non-epithelioid malignant pleural mesothelioma.
This positive opinion from the CHMP is a crucial step towards gaining full marketing authorization from the European Commission, with a decision expected by the end of the year. The U.S. Food and Drug Administration had previously approved this Keytruda combination in September.
The expansion into malignant pleural mesothelioma further broadens Keytruda's extensive label, which already includes dozens of indications worldwide. This development reinforces Keytruda's position as a leading cancer immunotherapy and contributes to Merck's oncology revenue.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.